Glaxo Wellcome Report issue

Contributed to NME For profit Phase 1 Phase 2 Phase 3 Phase 4
Founded: London United Kingdom (1995)
Status: Acquired by GlaxoSmithKline (2000)

Organization Overview

First Clinical Trial
1998
NCT00007670
First Marketed Drug
1995
epoprostenol (veletri)
First NDA Approval
1995
epoprostenol (veletri)
Last Known Activity
2003

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Active Ingredients

Marketed Drugs (8)

Key: Glaxo Wellcome (7) Acquired (1)

abacavir (ziagen) (NDA)

alosetron (lotronex) (2000 NDA)

epoprostenol (veletri) (1995 NDA)

lamivudine (epivir) (NDA)

pazopanib (votrient) (2002)

remifentanil (ultiva) (1996 NDA)

valaciclovir (Valtrex) (NDA)

zanamivir (relenza) (1999 NDA)

Drugs in Phase 4 Trials (13)

Key: Glaxo Wellcome (11) Acquired (2)

abacavir (ziagen) (31 trials)

amprenavir (agenerase) (18 trials)

didanosine (videx) (18 trials)

efavirenz (sustiva) (7 trials)

hepatitis b vaccine (recombinant) (Recombivax) (1 trial)

hydroxyurea (hydrea) (1 trial)

lamivudine (epivir) (28 trials)

nelfinavir (viracept) (9 trials)

ritonavir (Norvir) (3 trials)

stavudine (zerit) (4 trials)

sulfamethoxazole (gantanol) (5 trials)

trimethoprim (5 trials)

zidovudine (retrovir) (68 trials)

Drugs in Phase 3 Trials (18)

Key: Glaxo Wellcome (13) Acquired (5)

aciclovir (zovirax) (8 trials)

atovaquone (mepron) (7 trials)

carbamazepine (tegretol) (1 trial)

clindamycin (cleocin) (2 trials)

dapsone (aczone) (1 trial)

darbepoetin alfa (aranesp) (2 trials)

epoetin (Epogen) (4 trials)

fosamprenavir (lexiva) (2 trials)

gabapentin (neurontin) (1 trial)

indinavir (crixivan) (7 trials)

lamotrigine (lamictal) (1 trial)

methoxy polyethylene glycol-epoetin beta (Mircera) (1 trial)

netivudine (1 trial)

peginesatide (Omontys) (17 trials)

pentamidine (pentam) (2 trials)

primaquine (1 trial)

valaciclovir (Valtrex) (6 trials)

zalcitabine (hivid) (9 trials)

Drugs in Phase 2 Trials (15)

Key: Glaxo Wellcome (14) Acquired (1)

adefovir dipivoxil (hepsera) (2 trials)

anti-hiv immune serum globulin (human) (1 trial)

atorvastatin (lipitor) (1 trial)

azithromycin (zithromax) (1 trial)

beclomethasone (vanceril) (1 trial)

cefuroxime (zinacef) (1 trial)

eniluracil (1 trial)

glycovir (Celgosivir) (1 trial)

guaifenesin (1 trial)

interferon alpha-2b (Intron-A) (3 trials)

nevirapine (viramune) (3 trials)

pseudoephedrine (Benylin) (1 trial)

ranitidine (zantac) (1 trial)

saquinavir (invirase) (2 trials)

sorivudine (1 trial)

Drugs in Phase 1 Trials (10)

alvircept sudotox (1 trial)

atevirdine (2 trials)

emtricitabine (emtriva) (1 trial)

leucovorin (2 trials)

maribavir (Livtencity) (1 trial)

methadone (methadose) (1 trial)

nimodipine (nimotop) (1 trial)

pyrimethamine (daraprim) (2 trials)

raluridine (1 trial)

rgp120/hiv-1mn (1 trial)

Drugs in Other Trials (4)

aldesleukin (Proleukin) (1 trial)

bacitracin (polysporin) (1 trial)

polymyxin b sulfate (poly-rx) (1 trial)

trifluridine (viroptic) (1 trial)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 142
  • # of Trial APIs: 60